Ovarian cancer is one of the deadliest cancers affecting women. It causes more deaths than any other cancer of the female reproductive system, with an overall five-year survival rate of 52%, meaning roughly half of those diagnosed will not survive five years. That figure, however, masks enormous variation depending on when the cancer is caught and what type it is.
Why the Survival Rate Is So Low
The single biggest reason ovarian cancer is so lethal is that most cases are found late. When the disease is still confined to the ovary, the five-year survival rate is nearly 92%. Once it has spread to distant sites in the body, that number drops to about 31.5%. Unfortunately, distant-stage disease is far more common at diagnosis than localized disease, which dramatically pulls down the overall survival figure.
There is no reliable screening test for ovarian cancer. A blood marker called CA-125 and transvaginal ultrasound have both been studied extensively, but neither is accurate enough to justify routine screening in women at average risk. The Society of Gynecologic Oncology has stated there is insufficient evidence to support routine screening with either tool. That leaves most women relying on symptom recognition, and ovarian cancer’s early symptoms (bloating, pelvic pressure, feeling full quickly, urinary changes) overlap with dozens of common, benign conditions.
How Ovarian Cancer Spreads
The ovaries sit inside the abdominal cavity without a protective lining separating them from surrounding tissue. That anatomical detail matters: cancer cells can shed directly off the ovary’s surface and float freely through the abdominal fluid. From there, they implant on the lining of the abdomen or on the omentum, a fatty tissue layer that drapes over the intestines. This route of spread is essentially passive. The fluid itself contains growth-promoting molecules that help cancer cells survive their journey, and tiny cell-derived particles called exosomes help prepare distant tissue to accept new tumor implants.
Once cancer cells seed the abdominal lining, they recruit surrounding normal cells to support their growth. This cooperation between tumor and healthy tissue fuels further spread and is a major reason outcomes are poor in advanced disease. Fluid can accumulate in the abdomen as a result, a condition called ascites, which contains immune-suppressing cells that shield the cancer from the body’s natural defenses.
Recurrence Is Common
Even among women who respond well to initial treatment, ovarian cancer has a high recurrence rate. About 25% of women diagnosed at an early stage will see their cancer return. For those diagnosed at advanced stages, recurrence happens in more than 80% of cases.
After a first recurrence, the disease is rarely cured. Second-line treatment can still produce meaningful responses, especially when the cancer remains sensitive to platinum-based chemotherapy. But with each subsequent recurrence, treatment options narrow and effectiveness declines. Women whose cancer stops responding to platinum-based therapy face significantly worse outcomes and fewer viable treatment paths.
Not All Ovarian Cancers Are Equally Deadly
Ovarian cancer is not a single disease. It includes several subtypes with very different survival profiles, particularly in advanced cases. Among women with stage IV disease, five-year survival rates break down roughly as follows:
- Endometrioid: about 39%, the highest of the major subtypes
- High-grade serous: about 28%, the most common subtype overall
- Clear cell: about 19%
- Mucinous: about 14%, with a median survival of just nine months at stage IV
High-grade serous is by far the most frequently diagnosed type and drives most of the overall statistics people see. Mucinous ovarian cancer, while rarer, is notably more aggressive in advanced stages and responds poorly to standard chemotherapy. Clear cell tumors fall somewhere in between, with outcomes significantly worse than the serous type when matched by stage.
Genetic Mutations Can Change the Outlook
Women who carry BRCA1 or BRCA2 gene mutations face a higher lifetime risk of developing ovarian cancer, but there is an unexpected silver lining. These same mutations make tumor cells less capable of repairing their own DNA, which makes them more vulnerable to platinum-based chemotherapy. A large meta-analysis found that BRCA carriers had roughly 33% better overall survival compared to non-carriers. BRCA2 carriers benefited even more, with a 43% improvement in overall survival.
This is one of the clearest examples in oncology where the same genetic flaw that causes a cancer also makes it more treatable. It also means that genetic testing results carry practical implications for treatment planning, not just risk assessment.
Mortality Trends Are Moving in the Wrong Direction
Global mortality from ovarian cancer linked to high body mass index has been rising, with age-standardized death rates increasing by about 0.4% per year overall. More concerning, between 2020 and 2023, mortality from ovarian cancer accelerated sharply, growing at 2.4% per year. This uptick coincides with the COVID-19 pandemic period, during which cancer screenings and follow-up care were widely disrupted. Whether this acceleration will persist remains uncertain, but it reversed a period of modest decline that had lasted from 2003 to 2011.
The overall global mortality rate for ovarian cancer stood at 4.6 deaths per 100,000 women in 2023. While that number sounds small, it reflects the cumulative toll of a cancer that is difficult to detect, prone to recurrence, and increasingly linked to rising obesity rates worldwide.